Celgene Corporation (CELG) Shares Sold by Sectoral Asset Management Inc

Sectoral Asset Management Inc reduced its position in Celgene Corporation (NASDAQ:CELG) by 14.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 233,768 shares of the biopharmaceutical company’s stock after selling 38,298 shares during the quarter. Celgene comprises approximately 3.3% of Sectoral Asset Management Inc’s portfolio, making the stock its 10th biggest position. Sectoral Asset Management Inc’s holdings in Celgene were worth $30,359,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Neuberger Berman Group LLC boosted its holdings in shares of Celgene by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares during the period. Grisanti Capital Management LLC acquired a new stake in shares of Celgene in the second quarter valued at approximately $3,616,000. Lincoln Capital Corp boosted its holdings in shares of Celgene by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares during the period. RiverPoint Capital Management LLC boosted its holdings in shares of Celgene by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after acquiring an additional 3,680 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Celgene by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares during the period. 80.17% of the stock is owned by institutional investors and hedge funds.

In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.

CELG has been the subject of several research analyst reports. Jefferies Group reissued a “buy” rating and issued a $160.00 price objective on shares of Celgene in a report on Friday, September 15th. Mizuho increased their price target on Celgene from $134.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price target for the company. in a report on Tuesday, August 29th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene in a report on Monday, August 28th. Finally, Bank of America reaffirmed a “buy” rating on shares of Celgene in a report on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $139.57.

Celgene Corporation (NASDAQ CELG) opened at $102.61 on Tuesday. The stock has a market capitalization of $80,790.00, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 0.79 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.58 earnings per share. equities analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/05/celgene-corporation-celg-shares-sold-by-sectoral-asset-management-inc.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit